Indivior

100 articles about Indivior

• Indivior Announces Q4 / FY 2023 Financial Results

  2/22/2024

  Indivior PLC announced its financial results for the period ending December 31, 2023.

• Indivior Announces Q3 2023 Financial Results

  11/9/2023

  Indivior PLC announced its financial results for the period ending September 30, 2023.

• 

  As Impact of Substance Use Disorders Rise, So Do Innovative Solutions

  9/18/2023

  From reversing overdose to blocking cravings, the biopharma industry is looking at a range of possible solutions to addiction.

• C4X Discovery Holdings PLC Announces Divestment of Orexin-1 to Indivior for £15.95m

  8/1/2023

  C4X Discovery Holdings plc, a pioneering Drug Discovery company, announces the execution of an asset purchase agreement for Indivior PLC to acquire the proprietary rights to C4XD's oral Orexin-1 receptor antagonist, C4X_3256 for substance use disorder, for £15.95 million.

• Indivior Announces Q2/H1 2023 Financial Results

  7/27/2023

  Indivior PLC announced its financial results for the period ending June 30, 2023.

• Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence

  6/14/2023

  Indivior PLC announced the acceptance of four abstracts for presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence taking place June 17-21, 2023, in Denver, Colorado.

• Indivior to Commence Trading on Nasdaq

  6/12/2023

  Indivior PLC announces that the U.S. Securities & Exchange Commission declared its registration statement on Form 20-F effective on June 9.

• Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims

  6/2/2023

  Indivior PLC, a leading addiction treatment company, announced that its subsidiary, Indivior Inc., has reached an agreement to resolve the claims brought by the Attorneys General of 41 states and the District of Columbia in the In re Suboxone Antitrust Litigation multi-district litigation.

• Indivior To Participate In Upcoming June 2023 Investor Conferences

  5/25/2023

  Indivior PLC announced that it will participate in the following investor events:

• Indivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12th

  5/23/2023

  Indivior PLC announced that its registration statement on Form 20-F required for the additional U.S. listing of its ordinary shares is now available at www.sec.gov and under the "Investors" section of the Company's website.

• 

  FDA Approves First Nasal Nalmefene Spray for Opioid Overdose

  5/23/2023

  Indivior's Opvee is an emergency nasal spray medication to reverse opioid overdose approved for patients aged 12 years and above with signs of respiratory or central nervous system depression.

• Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl

  5/22/2023

  Indivior PLC (LSE: INDV) today announced that the U.S. Food and Drug Administration (FDA) approved OPVEE® (nalmefene) nasal spray for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression.

• Indivior Announces Q1 2023 Financial Results

  4/27/2023

  Indivior PLC (LSE: INDV) today announced its financial results for the period ending March 31, 2023.

• Indivior To Participate In Bank of America Global Healthcare Conference 2023

  4/25/2023

  Indivior PLC (LSE: INDV) today announced that it will participate in the following investor event.

• FY 2022 Financial Results Announced

  2/16/2023

  Indivior PLC announced 2022 Full Year Results.

• 

  Market Skeptical Following Sen. Warren's Antitrust Allegations

  1/27/2023

  Sen. Elizabeth Warren (D-MA) voiced concerns to the FTC regarding the prospective acquisitions of Horizon Pharmaceuticals and Opiant Pharmaceuticals by Amgen and Indivior.

• Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook

  12/7/2022

  Indivior PLC will hold a Capital Markets Day in New York City. The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team and will detail the Company's strategic growth plans and roadmap for delivering long-term shareholder value.

• 

  Indivior Bets $145M on Opiant’s Opioid Overdose Recovery Candidate

  11/14/2022

  Indivior PLC announced it will acquire Opiant Pharmaceuticals and its lead candidate OPNT003, an intranasal-delivered opioid overdose recovery product.

• Indivior To Acquire Opiant Pharmaceuticals

  11/14/2022

  Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in cash, plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch.

• Indivior PLC to Acquire Opiant Pharmaceuticals

  11/14/2022

  Opiant Pharmaceuticals Inc. announced that it has entered into a definitive merger agreement to be acquired by Indivior Inc, a subsidiary of Indivior PLC.